Memorial Sloan Kettering Cancer Center shared on LinkedIn:
“Memorial Sloan Kettering Cancer Center (MSK) is honored to be named as a 2026 leader in biomedical translational research by the Cure Innovation Index.
MSK was ranked the 4th most innovation institution from among 60 major institutes and centers (and the top performing cancer center) with special distinction for our research capabilities and performance in translational research.
Dr. Yashodhara Dash, Vice President of Commercialization and Entrepreneurship:
“MSK’s strong standing in this year’s Innovation Index reflects a sustained commitment to translating exceptional science into meaningful impact for patients. This recognition signals the depth of our ecosystem, from discovery through development to real-world adoption,”
Other articles featuring Yashodhara Dash on OncoDaily.